Overview
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The addition of a Drug Affinity Complex (DAC) — a lysine-maleimidoproprionic acid linker — allows it to bind covalently to circulating albumin, dramatically extending its half-life from minutes (native GHRH) to approximately 6–8 days.
Mechanism
CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating GH synthesis and secretion. The DAC modification enables albumin binding, extending the half-life and producing sustained elevation of GH and IGF-1 levels in research models.
Research Areas
-
GH Axis Research
CJC-1295 is widely used in research to study sustained GH pulse amplification and its downstream effects on IGF-1.
-
Muscle & Bone Research
Studies have examined the effects of sustained GH elevation on lean mass accrual and bone mineral density in animal models.
-
Metabolism Research
Research has explored GH-mediated lipolysis and its effects on adipose tissue distribution in laboratory settings.
-
Combination Research
CJC-1295 is frequently studied in combination with Ipamorelin to examine synergistic GH secretagogue effects.
Storage
Store lyophilized at -20°C. Reconstitute with bacteriostatic water. Refrigerate at 4°C and use within 30 days.